May 22, 2008 - MIV Therapeutics Inc. has enrolled the first patients in the registration trial of its VESTAsync polymer-free drug-eluting stent, as the company accelerates its timeline for the VESTASYNC II trial after positive nine-month human safety and efficacy data were reported in March at the American College of Cardiology meeting.

Medtronic introduced Profile 3D Annuloplasty Ring with a design based on the geometry of the saddle-shaped human mitral annulus to promote natural function with the aim of repairing rather than replacing a failing mitral valve.

The Profile 3D ring design is based data strongly suggesting that nature conserves the saddle-shaped annulus for a mechanical benefit. Specifically, leaflet stress can be related to saddle height, which could affect long-term durability of the repair.

May 21, 2008 - Hospitals are increasingly using real-time locating systems (RTLS) so clinicians know where to find the equipment they need or patients at any moment on a computerized map of the hospital. There are several technologies for RTLS tracking that use radio frequency identification (RFID), ultrasound or infrared emitting tags that are detected on a wireless network.

May 21, 2008 - At the Heart Rhythm 2008 President's Reception on Friday, May 16, outgoing President Bruce Lindsay, M.D., FHRS, passed the gavel to incoming President N.A. Mark Estes, III, M.D., FHRS, in a ceremony where Dr. Estes said he would focus the society's efforts on "three major areas during the next year: strategic planning, education and health policy and advocacy."

May 21, 2008 - Biosense Webster showed its 'Complete Ablation Solutions' portfolio at the Heart Rhythm Society's (HRS) 29th Annual Scientific Sessions by featuring its Complete Ablation Solutions.

Complete Ablation Solutions represents Biosense Webster's exclusive focus on ablation therapy, its complete portfolio of its technologies and products, coupled with an array of solutions, including professional education and clinical support, global education and training programs, technical services, patient education and ablation practice building initiatives.

May 21, 2008 - St. Jude Medical Inc. released its EnSite System Version 8.0, software designed to intuitively visualize the anatomy of the heart to diagnose and treat abnormal heart rhythms, at Heart Rhythm 2008.

May 21, 2008 - Antiarrhythmic drug treatment during the six weeks following atrial fibrillation (AF) ablation is well tolerated and reduces the incidence of clinically significant atrial arrhythmias and the need for cardioversion or hospitalization, according to new research released at Heart Rhythm 2008, the Heart Rhythm Society’s 29th Annual Scientific Sessions.

May 21, 2008 - More than half of patients primarily receive information about device recalls from the media and not from their cardiologist, said two studies on patient perspectives on device recalls presented at Heart Rhythm 2008, the Heart Rhythm Society’s 29th Annual Scientific Sessions.

This is despite the fact that nearly 80 percent of patients said they prefer to receive cardiac device recall information directly from their cardiologist, the studies reported.

May 21, 2008 - Dronedarone significantly reduces the incidence of cardiovascular hospitalization or death in patients with atrial fibrillation (AF), according to results of the ATHENA Trial presented at Heart Rhythm 2008.

May 21, 2008 - Physicians can detect and diagnose clinically actionable events earlier in pacemaker patients who utilize remote interrogation compared to those that are followed via routine office visits augmented by transtelephonic monitoring (TTM), according to the PREFER Trial, a late-breaking clinical trial presented at Heart Rhythm 2008, the Heart Rhythm Society’s 29th Annual Scientific Sessions.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now